Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 5 years of Total Non-Current Liabilities data on record, last reported at $130.9 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 20.17% year-over-year to $130.9 million; the TTM value through Dec 2025 reached $130.9 million, up 20.17%, while the annual FY2025 figure was $130.9 million, 20.17% up from the prior year.
  • Total Non-Current Liabilities reached $130.9 million in Q4 2025 per CRNX's latest filing, up from $121.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $130.9 million in Q4 2025 and bottomed at $96.2 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $110.9 million, with a median of $107.3 million recorded in 2024.
  • The widest YoY moves for Total Non-Current Liabilities: up 20.17% in 2025, down 10.66% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $96.2 million in 2023, then rose by 13.21% to $109.0 million in 2024, then rose by 20.17% to $130.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $130.9 million in Q4 2025, $121.0 million in Q3 2025, and $115.7 million in Q2 2025.